Boekel Naomi B, Schaapveld Michael, Gietema Jourik A, Rutgers Emiel J T, Versteegh Michel I M, Visser Otto, Aleman Berthe M P, van Leeuwen Flora E
Psychosocial research and Epidemiology (NBB, MS, FEvL), Surgery (EJTR), and Radiation Oncology (BMPA), Netherlands Cancer Institute, Amsterdam, The Netherlands; Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands (JAG); Steering Committee Cardiac Interventions Netherlands, Leiden University Medical Center, Leiden, The Netherlands (MIMV); Registration and Research, Comprehensive Cancer Center the Netherlands, Utrecht, The Netherlands (OV).
J Natl Cancer Inst. 2014 Aug 15;106(8). doi: 10.1093/jnci/dju156. Print 2014 Aug.
Recent concerns about potential overdiagnosis and overtreatment of ductal carcinoma in situ of the breast (DCIS) render evaluation of late effects of treatment, such as cardiovascular disease (CVD), of great importance. We studied cardiovascular morbidity and mortality in a large population-based cohort of DCIS patients.
Data on all incident DCIS case patients in the Netherlands between 1989 and 2004 who were diagnosed before the age of 75 years were obtained (n = 10468). CVD data was acquired through linkage with population-based registries. Standardized mortality ratios were calculated by comparing mortality in our cohort with that in the Dutch female population, taking into account person-years of observation. Within-cohort comparisons were based on multivariable competing-risk regression.
Compared with the general population, 5-year survivors of DCIS had a similar risk of dying due to any cause (standardized mortality ratio [SMR] = 1.04; 95% confidence interval [CI] = 0.97 to 1.11) but a lower risk of dying of CVD (SMR = 0.77; 95% CI = 0.67 to 0.89). No difference in CVD risk was found when comparing 5-year survivors treated with radiotherapy with those treated with surgery only. Left-sided vs right-sided radiotherapy also did not increase this risk (hazard ratio [HR] = 0.94; 95% CI = 0.67 to 1.32). In a subgroup analysis of all DCIS patients diagnosed between 1997 and 2005, we were able to account for history of CVD and did not observe a risk difference between treatment groups (left-sided vs right-sided radiotherapy: HR = 0.94; 95% CI = 0.68 to 1.29).
After a median follow-up of 10 years, we did not find an increased risk for cardiovascular morbidity or mortality after radiotherapy for DCIS when comparing surgery and radiotherapy vs surgery only, nor when comparing radiotherapy for left-sided vs right-sided DCIS. Compared with the general population, DCIS patients have a decreased risk of cardiovascular death, independent of treatment.
近期对乳腺导管原位癌(DCIS)潜在的过度诊断和过度治疗的担忧使得评估治疗的晚期效应(如心血管疾病(CVD))变得极为重要。我们研究了一个基于人群的大型DCIS患者队列中的心血管发病率和死亡率。
获取了1989年至2004年间荷兰所有75岁之前确诊的DCIS病例患者的数据(n = 10468)。通过与基于人群的登记处进行关联来获取CVD数据。在考虑观察人年数的情况下,通过将我们队列中的死亡率与荷兰女性人群中的死亡率进行比较来计算标准化死亡率。队列内比较基于多变量竞争风险回归。
与一般人群相比,DCIS的5年幸存者因任何原因死亡的风险相似(标准化死亡率[SMR] = 1.04;95%置信区间[CI] = 0.97至1.11),但死于CVD的风险较低(SMR = 0.77;95% CI = 0.67至0.89)。比较接受放疗的5年幸存者和仅接受手术治疗的幸存者时,未发现CVD风险存在差异。左侧放疗与右侧放疗也未增加这种风险(风险比[HR] = 0.94;95% CI = 0.67至1.32)。在对1997年至2005年间确诊的所有DCIS患者进行的亚组分析中,我们考虑了CVD病史,未观察到治疗组之间存在风险差异(左侧放疗与右侧放疗:HR = 0.94;95% CI = 0.68至1.29)。
在中位随访10年后,我们发现,比较手术加放疗与仅手术治疗时,以及比较左侧DCIS放疗与右侧DCIS放疗时,DCIS放疗后心血管发病率或死亡率均未增加。与一般人群相比,DCIS患者心血管死亡风险降低,与治疗无关。